|
| extended-release Naltrexone (Vivitrol 380 mg) (n = 1500) | long-acting Nalmefene (Nalmefene Consta 393.1 mg) (n = 1500) |
| Alanine aminotransferase increased | 150 (10%) | 90 (6%) |
| Aspartate aminotransferase increased | 90 (6%) | 30 (2%) |
| Gamma-glutamyltransferase increased | 60 (4%) | 45 (3%) |
| Nasopharyngitis | 120 (8%) | 60 (4%) |
| Insomnia | 120 (8%) | 45 (3%) |
| Influenza | 75 (5%) | 60 (4%) |
| Hypertension | 60 (4%) | 45 (3%) |
| Injection site pain | 120 (8%) | 30 (2%) |
| Toothache | 60 (4%) | 30 (2%) |
| Headache | 45 (3%) | 30 (2%) |